// App-Quantinova.ai

AB0434 (2022) : EFFICACY AND SAFETY OF OBINUTUZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH SECONDARY NON-RESPONSE TO RITUXIMAB.

Researchers

Presenter

  • J. Arnold

Principal Investigators

  • S. Dass

  • S. Twigg

  • C. Jones

  • B. Rhodes

  • P. Hewins

  • M. Chakravorty

  • P. Courtney

  • M. Ehrenstein

  • M. Y. Md. Yusof

  • E. Vital

Medical Centers

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • Leeds Teaching Hospitals NHS Trust and NIHR Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom

  • Bradford Teaching Hospitals NHS Trust, Cardiology, Bradford, United Kingdom

  • York Teaching Hospitals NHS Foundation Trust, Nephrology, York, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

  • University College London, Gastroenterology, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Methylprednisolone

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • GlaxoSmithKline (GSK)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved